Interpreting success or failure of peanut oral immunotherapy
Peanut oral immunotherapy (OIT) was recently approved by the US FDA. However, not all patients respond to OIT, and there is a high likelihood of regaining sensitization to peanuts after cessation of treatment. It is important, therefore, to identify biomarkers that impact and predict OIT outcomes. I...
Saved in:
Published in | The Journal of clinical investigation Vol. 132; no. 2 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
United States
American Society for Clinical Investigation
18.01.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!